News for 'sun-pharma'

'14+ Anti-Obesity Drugs In The Pipeline'

'14+ Anti-Obesity Drugs In The Pipeline'

Rediff.com13 Dec 2025

The semaglutide patent expiry next year could unleash a wave of generic versions from Indian drugmakers, with prices expected to go lower -- at least 80 per cent.

Ranbaxy, Sun Pharma gain as CCI clears deal

Ranbaxy, Sun Pharma gain as CCI clears deal

Rediff.com9 Dec 2014

Shares of Ranbaxy Lab and Sun Pharma on Tuesday gained as much as 4 per cent after the drug-makers got CCI's approval for their long-pending $4-billion merger.

Sun Pharma settles litigation with Novartis over cancer drug

Sun Pharma settles litigation with Novartis over cancer drug

Rediff.com15 May 2014

One of the subsidiaries of Sun Pharma has executed a settlement agreement with Novartis, stipulating a dismissal of the lawsuits filed in the United States against the company regarding submission of an Abbreviated New Drug Application for a generic version of Gleevec, the Indian drug major said in a statement.

Sensex, Nifty close marginally lower after hitting fresh lifetime highs

Sensex, Nifty close marginally lower after hitting fresh lifetime highs

Rediff.com1 Dec 2025

Among Sensex firms, Bajaj Finance, Sun Pharma, Trent, Mahindra & Mahindra, State Bank of India and Bajaj Finserv were the major laggards. However, Tata Motors Passenger Vehicles, Maruti, Bharat Electronics, Kotak Mahindra Bank, Adani Ports and HCL Tech were among the gainers.

Sun Pharma launches cancer drug

Sun Pharma launches cancer drug

Rediff.com31 Mar 2008

Drug maker Sun Pharmaceutical Industries on Monday said it has commercially launched generic Ethyol, used in the treatment of cancer. Ethyol is the generic version of Medimmune's Ethyol amifostine injection, used for treating cancer, Sun Pharma informed the Bombay Stock Exchange, adding that the drug has an annual sales of $80 million in the US.

Stock markets rally on US Fed rate cut hopes, fresh foreign fund inflows

Stock markets rally on US Fed rate cut hopes, fresh foreign fund inflows

Rediff.com29 Oct 2025

From the Sensex firms, Adani Ports, NTPC, Power Grid, HCL Tech, Tata Steel, Sun Pharma, Trent and Asian Paints were among the major gainers. However, Bharat Electronics, Eternal, Mahindra & Mahindra and Maruti were among the laggards.

USFDA pulls up Sun Pharma for lapses in Halol plant

USFDA pulls up Sun Pharma for lapses in Halol plant

Rediff.com14 Jan 2023

The US health regulator has pulled up drug major Sun Pharma for manufacturing lapses, including failure to follow appropriate written procedures designed to prevent microbiological contamination of drug products, at its Gujarat-based plant. In a warning letter, the US Food and Drug Administration (USFDA) pointed out various lapses at the Halol plant which produces finished pharmaceutical products. "This warning letter summarises significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals... Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated," the USFDA stated.

Stock markets rally as RBI cuts rate; Sensex jumps 447 points

Stock markets rally as RBI cuts rate; Sensex jumps 447 points

Rediff.com5 Dec 2025

From the Sensex firms, State Bank of India, Bajaj Finserv, Bajaj Finance, Maruti, HCL Tech, Larsen & Toubro, Mahindra & Mahindra and Infosys were among the major winners. However, Hindustan Unilever, Eternal, Tata Motors Passenger Vehicles, and Sun Pharma were among the laggards.

Sun Pharma to acquire US-based DUSA for $230 million

Sun Pharma to acquire US-based DUSA for $230 million

Rediff.com8 Nov 2012

DUSA is a dermatology company focused on developing and marketing its Levulan photodynamic therapy platform.

Meet the man behind the Sun Pharma-Ranbaxy deal

Meet the man behind the Sun Pharma-Ranbaxy deal

Rediff.com8 Apr 2014

Sun Pharma's offer was tempting because Ranbaxy was too busy fighting fires in the US to concentrate on operations.

Looking for more acquisition: Sun Pharma

Looking for more acquisition: Sun Pharma

Rediff.com9 Nov 2012

Sun Pharma's managing director Dilip Shanghvi, says we continue to look for opportunities to expand our business in all the key geographies and markets we are focused on.

Merger woes: Sun Pharma asks some Ranbaxy staff to leave

Merger woes: Sun Pharma asks some Ranbaxy staff to leave

Rediff.com18 Jun 2015

Nearly 150 senior management staff will be asked to leave.

Indian bourses' nod for Sun Pharma-Ranbaxy deal

Indian bourses' nod for Sun Pharma-Ranbaxy deal

Rediff.com21 Jul 2014

The deal had separately come under scanner of the market regulator Sebi for alleged insider trading violations and the present 'no-objection' from the exchanges.

Sun Pharma draws up plan to fix ailing Ranbaxy

Sun Pharma draws up plan to fix ailing Ranbaxy

Rediff.com12 Sep 2014

It hopes to turn around Ranbaxy within four years of closing the deal by improving efficiency and resolving all regulatory issues

Sun Pharma to delist Ranbaxy on completion of $4-bn merger

Sun Pharma to delist Ranbaxy on completion of $4-bn merger

Rediff.com25 Mar 2015

The merger has fortified Sun Pharma's position.

Selling in blue-chips RIL, HDFC Bank drag Sensex down by 153 points

Selling in blue-chips RIL, HDFC Bank drag Sensex down by 153 points

Rediff.com8 Oct 2025

Among Sensex firms, Tata Motors, Mahindra & Mahindra, Bharat Electronics, UltraTech Cement, Trent, Sun Pharma, Power Grid and Reliance Industries were the major laggards. However, Titan, Infosys, Tata Consultancy Services, HCL Tech and Tech Mahindra were among the biggest gainers.

Sun Pharma gets US trade regulator nod for Ranbaxy deal

Sun Pharma gets US trade regulator nod for Ranbaxy deal

Rediff.com2 Feb 2015

Ranbaxy was asked to sell all products containing Leuprorelin which are marketed and supplied under brand name Eligard.

Maintain status-quo on Sun Pharma-Ranbaxy merger: HC to bourses

Maintain status-quo on Sun Pharma-Ranbaxy merger: HC to bourses

Rediff.com29 Apr 2014

Based on a writ petition filed by some individual investors, the High Court while ordering the status quo on Friday, issued notices to SEBI, BSE, NSE, Sun Pharma, Ranbaxy, Daichii Sankyo and Silver Street Developers.

Indian Pharma Majors Ready With Weight Loss Drugs

Indian Pharma Majors Ready With Weight Loss Drugs

Rediff.com12 Aug 2025

Prices for Indian consumers are expected to come down significantly from the current Rs 17,000-Rs 26,000 monthly.

Andhra HC order not to impact merger with Ranbaxy: Sun Pharma

Andhra HC order not to impact merger with Ranbaxy: Sun Pharma

Rediff.com27 May 2014

Last week, the court had vacated the status quo order it had issued earlier on the merger process between Sun Pharma and Ranbaxy.

Sensex jumps 1,022.50 points; Nifty inches near record high

Sensex jumps 1,022.50 points; Nifty inches near record high

Rediff.com26 Nov 2025

Among Sensex firms, Bajaj Finserv, Bajaj Finance, Tata Steel, Reliance Industries, Sun Pharma, Tata Motors Passenger Vehicles, Axis Bank and Infosys were among the major gainers. Bharti Airtel and Asian Paints emerged as the laggards from the pack.

Sensex falls 388 points; Adani stocks rally

Sensex falls 388 points; Adani stocks rally

Rediff.com19 Sep 2025

Among Sensex firms, HCL Tech, ICICI Bank, Titan, Trent, Kotak Mahindra Bank, Hindustan Unilever, Mahindra & Mahindra and HDFC Bank were the major laggards. However, Adani Ports, Bharti Airtel, SBI, NTPC and Sun Pharma were among the gainers.

Shareholders' nod for Sun Pharma spin-off

Shareholders' nod for Sun Pharma spin-off

Rediff.com23 Feb 2013

The report of the January 25 meeting was placed before the high court last week.

Sun Pharma arm buys US co

Sun Pharma arm buys US co

Rediff.com26 Dec 2005

Sun Pharmaceutical Industries Ltd on Monday said its Michigan-based wholly owned subsidiary,

Sensex ends above 83K buoyed by US Fed rate cut

Sensex ends above 83K buoyed by US Fed rate cut

Rediff.com18 Sep 2025

Among Sensex firms, Eternal, Sun Pharma, Infosys, HDFC Bank, HCL Tech, Hindustan Unilever, Power Grid, ITC and Adani Ports were the major gainers. However, Tata Motors, Trent, Bajaj Finance and Asian Paints were among the laggards.

The success story of Sun Pharma

The success story of Sun Pharma

Rediff.com25 May 2007

For a company that started in 1983 with just five people and five products, it's no mean achievement that Sun Pharma today commands the largest market capitalisation of Rs 21,271 crore (Rs 212.71 billion) in the pharma universe.

 Sun Pharma slumps after $550 mn patent suit settlement with Pfizer

Sun Pharma slumps after $550 mn patent suit settlement with Pfizer

Rediff.com13 Jun 2013

Shares in Sun Pharmaceutical Industries fell by more than 5 per cent after the company settled a patent suit with Pfizer Inc related to its acid-reflux drug for $550 million.

Sun Pharma has all the reasons to cheer Ranbaxy deal

Sun Pharma has all the reasons to cheer Ranbaxy deal

Rediff.com11 Apr 2014

One of the suitors says that Ranbaxy's Indian portfolio alone is worth $2 billion, or approximately Rs 11,900 crore.

Weightloss Drugs Hit 1,000 Crore Mark

Weightloss Drugs Hit 1,000 Crore Mark

Rediff.com22 Dec 2025

'As more patients are prescribed these drugs, intolerance due to gastrointestinal and other side effects will become more visible, leading to higher discontinuation rates.'

Pharma stocks slide as US headwinds hurt

Pharma stocks slide as US headwinds hurt

Rediff.com16 Sep 2025

Concerns over weakening demand for Indian pharmaceutical (pharma) drugs in the US - their largest export market - have weighed heavily on investor sentiment this year. While the Nifty 50 has gained 6.02 per cent year - to - date (as on September 15), the Nifty Pharma index has declined 5.18 per cent, National Stock Exchange data shows.

Court orders temporary halt on Sun Pharma's takeover of Ranbaxy

Court orders temporary halt on Sun Pharma's takeover of Ranbaxy

Rediff.com1 May 2014

Two individuals filed the petition in the high court of Andhra Pradesh

Sun Pharma CEO on future plans

Sun Pharma CEO on future plans

Rediff.com9 May 2006

We believe that our R&D business has tremendous potential for growth and long-term profitability.

Sun Pharma hikes stake in Caraco

Sun Pharma hikes stake in Caraco

Rediff.com4 Feb 2004

Sun Pharmaceutical Industries Ltd has entered into an agreement with two large shareholders of its subsidiary Caraco Pharmaceutical Laboratories Ltd to acquire most of their common stock and options in the latter for $42 million.

Benefit of Ranbaxy deal to accrue in few years: Sun Pharma

Benefit of Ranbaxy deal to accrue in few years: Sun Pharma

Rediff.com29 Sep 2014

The proposed acquisition is expected to close by the end of 2014, subject to approvals from Indian Courts and the anti-trust body in India and the US

Will Tata Sons Get RBI Relief?

Will Tata Sons Get RBI Relief?

Rediff.com24 Oct 2025

Tata Sons, now debt-free, has asked the RBI to drop its 'upper-layer NBFC' tag and allow it to stay private.

Sun Pharma seeks shareholders' nod for Rs 12,000-crore QIP

Sun Pharma seeks shareholders' nod for Rs 12,000-crore QIP

Rediff.com12 Sep 2014

Sun Pharma stated the company wanted shareholders' approval to "issue, offer and allot equity shares or non-convertible securities, other than warrants, up to an amount of Rs 12,000 crore ($2 billion), to qualified institutional buyers pursuant to a QIP."

Sun Pharma moves SC against stay on Ranbaxy merger

Sun Pharma moves SC against stay on Ranbaxy merger

Rediff.com15 May 2014

Last month, the high court had ordered an interim status quo on the $4-billion deal, after a suit from some individual investors alleged insider trading in Ranbaxy's shares by Silverstreet Developers, Sun's wholly owned arm, before the deal was announced on April 6.

Sun Pharma buys controlling stake in Taro

Sun Pharma buys controlling stake in Taro

Rediff.com22 Sep 2010

Sun Pharmaceuticals on Wednesday said it has acquired a controlling stake in Israeli pharma major Taro Pharmaceuticals.

Sun Pharma profit down 30% over compliance costs, lower sales

Sun Pharma profit down 30% over compliance costs, lower sales

Rediff.com7 Nov 2015

Sun Pharma profit down 30% over compliance costs, lower sales.

Post takeover, Sun Pharma to rebrand Ranbaxy drugs in the US

Post takeover, Sun Pharma to rebrand Ranbaxy drugs in the US

Rediff.com9 Apr 2014

Ranbaxy drugs sold in the United States will be gradually rebranded as Sun Pharma treatments